How to Choose a Pharma Customer Experience Partner

A pharma CX agency is a firm engaged to design and govern how physicians, patients and the people around them move through a company's commercial system. The difficulty in hiring one is that at least three unrelated kinds of business answer to that description. A commercial leader can often see that earned value is disappearing somewhere between a prescribing decision and a patient on therapy. What that leader cannot see is which category of firm is built to work there.

Institutions tend to name a problem only after they have learned to govern it, and this one has no settled name yet. So a search returns strategy houses, research shops and creative agencies side by side, all of them speaking the same vocabulary. This page tries to make the choice legible, including the places where my own firm is the wrong answer. Read it as a buyer's guide written by one of the options, with the bias stated rather than hidden.

The buyer's real problem comes one step earlier

Most hiring conversations start too late. A leader arrives having already decided to buy help, then compares firms that are not comparable. The prior question is which part of the commercial system is failing. That determines the category of help, and the category matters more than the vendor.

The failure itself tends to look the same in every company. Earned value, meaning the value a brand has already won through evidence, access and a clinical decision, does not fully survive the trip to a patient on therapy. Scripts are written and some are never filled. Therapy starts and some of it stops early.

No competitor takes that difference, which is what separates value leakage from lost share. The term means contract slippage in general business, so the pharma sense needs stating. The loss here is largely experiential rather than clinical or promotional. That matters for hiring, because experiential failure sits between functions, and the firms selling into pharma are mostly organised to work inside one.

Three kinds of firm answer to the same words

Describe the three fairly and the choice gets easier. Each is genuinely good at something, each has a real limit, and a buyer who recognises a caricature of their current partner will stop reading. Nothing below is a judgment about anyone's competence.

The large strategy and analytics firms

These firms own the quantitative machinery of a commercial organization, and they own it properly. Data infrastructure, segmentation, targeting, incentive design, forecasting and the analytics sitting under a launch are their native ground. They are built to answer large questions at scale and with method.

Where they tend to stop is the handoff from recommendation to installed capability. The output is usually an answer rather than an operating model, and the work often concludes before the operating model has changed. Nothing about that is a flaw in the craft. The commercial arrangement pays for analysis rather than for the slow business of changing how functions hand work to each other.

The research and benchmarking firms

These firms measure how customers experience an industry and compare one company against its peers. The instruments are serious and the panels are expensive to build. For a leader who needs to know whether a problem is theirs or everybody's, this may be the right purchase.

Where they stop is the distance between a rank and a diagnosis. A benchmark tells you where you sit against a peer set, which is useful, and it is not the same as knowing which of your own journeys breaks, at which stage, or who owns the break. I have sat in rooms where a benchmark result was presented with real rigour and nobody present could name the next action. The measurement was sound and the accountability was entirely missing.

The brand and creative agencies

Narrative, identity, campaign and the design of what a customer actually sees are craft disciplines, and the good agencies are very good at them. They can change how a brand is understood in a market, which is not a small thing to be able to do.

Where they stop is a matter of geography rather than skill. Almost everything determining whether a prescription becomes therapy happens in places a campaign does not reach. Benefit verification, prior authorization, affordability support, pharmacy coordination and the first ninety days of a patient's own life are the territory of the Path to Fulfill and the Path to Adhere. A creative brief has no instrument that operates there.

Why is none of the three built for this?

The honest conclusion is that none of the three is wrong, and most companies need some of all of them. The analytics firms answer questions pharma cannot answer alone. The benchmarking firms supply comparability. The agencies build the brand that earns the clinical decision in the first place.

What none of them is engaged to do is govern whether earned value survives the journey. That problem sits across medical affairs, marketing, field, market access, patient services and the hub, and ownership of it is often distributed to the point of absence. A firm hired by one function will work inside that function's authority, which is exactly as far as the problem's edge.

There is a second reason the category stayed unnamed. Pharma tried importing consumer customer experience a decade ago and largely rejected it, because the first iterations genuinely did not fit the industry, and that rejection was rational. The wrong lesson drawn from it was that consumer CX does not translate to pharma and that experience is therefore a soft agenda, when the real conclusion was that pharma needed its own interpretation.

Internal confidence makes this harder to see than it should be. Deloitte 2025 research found only 28 percent of HCPs believe pharma's engagement strategies meet their needs, against 82 percent of life sciences executives who say they are satisfied with those same strategies, in work published by Deloitte. A gap that wide suggests the inside is measuring something other than what customers experience.

The questions to ask any firm you consider

The most useful preparation is to write seven questions and ask every firm the same seven, because the answers separate categories faster than any capability deck. What follows is roughly what a strong answer sounds like, and what a weak one sounds like.

Start with what will be measured. A strong answer names progression, meaning movement along a stage ladder from scripts written to filled, therapy started, ninety days and persistence. A weak answer names sentiment, satisfaction or a relationship score, which reports how customers feel rather than whether they moved forward.

Ask who owns the handoffs between functions once the engagement ends. A strong answer names roles, decision rights and an escalation path that still exists after the invoices stop. A weak answer describes a steering committee, which is a forum rather than an owner.

Ask what happens to the capability when the team leaves. A strong answer describes instrumentation, a cadence and people inside the company now running something they did not run before. A weak answer offers a playbook, and a playbook with no owner is simply a document.

Ask to be shown where value is lost on a specific brand, by stage, with a number attached. A strong answer is uncomfortable, specific and willing to be wrong in front of you. A weak answer retreats to industry averages, which cannot be acted on by anybody.

Ask how the work differs from what a benchmark would tell you. A strong answer is candid that a benchmark may be the cheaper and better purchase for the question you actually have. A weak answer tries to be both a benchmark and a transformation, and rarely manages either.

Ask which of the three paths the work will touch, and why that one. Prescribe, fulfill and adhere have different owners, failure modes and economics, so a firm treating them as one journey has not worked inside them. A strong answer picks one and defends the choice.

Last, ask what the firm would refuse to take on. A strong answer comes quickly, because a practice with a real method knows its own edges. A firm that can do everything has usually codified nothing.

When should you not hire anyone at all?

Three situations make an external engagement a poor use of money, and they are more common than this market tends to admit. Saying so costs me work occasionally, which seems a reasonable price for being useful here.

The first is the absence of a named owner. If no single executive is accountable for what happens between a prescribing decision and a patient on sustained therapy, an external firm will produce a report nobody has the authority to act on. The governance question comes before the vendor question, and who owns customer experience in pharma is rarely as settled as an organization chart suggests. Fix the ownership first, even when that takes a quarter.

The second is a decision already taken. If leadership wants a number to justify a direction it has chosen, that is a research purchase and should be bought as one, from a firm that sells research. Buying transformation to validate a conclusion wastes the budget. More expensively, it burns the organization's appetite for the real work later.

The third is a constraint sitting somewhere else entirely. If a brand's actual problem is clinical differentiation, formulary exclusion, supply or a label, experience work is not the lever and no amount of journey design will become one. Experience governs whether earned value survives, and it cannot earn value a brand has not yet won.

Where The Customer Excellence AGENCY fits

My own firm is a commercial systems architecture practice for pharma and life sciences. The work is the distance between a prescribing decision and a patient on sustained therapy. That stretch of the therapeutic value chain is what the industry files under commercialization, and it has never been held to a standard of its own. Customer Excellence is the capability that governs it, and the fourth of the four domains of commercial excellence beside launch, marketing and sales.

Three service lines carry the work. Accelerate Brand Growth begins with stalled growth as the symptom and traces where value is leaking, by stage, with numbers attached. Strengthen Field Performance treats the frontline as an intelligence system rather than only a channel, because field observation reaches a broken journey long before a dashboard detects it. Scale Customer Excellence makes the capability an enterprise one, with instrumentation and governance that outlast a programme.

What it is not

The firm is a boutique rather than a scaled analytics practice. There is no benchmark panel here and no syndicated data, so a company needing comparability against a peer set should buy that from a firm owning a panel. This is not a creative agency and it does not produce campaigns. A company whose real need is any of those three should buy those three, and I will say so early.

What should any engagement be measured against?

What distinguishes this work is the measure it is willing to accept. Scientific value is realized when the patient accesses, starts, continues and benefits, not when the script is written. Written prescriptions are intent rather than realized value. A commercial system that cannot tell the difference will keep reporting success at the moment its real work begins.

So any engagement should be judged on the Realization Rate of a pharmaceutical brand, meaning realized value divided by earned value, rather than on a satisfaction score. The measure matters more than the method, and it certainly matters more than the firm.

If the commercial system is a link in the therapeutic value chain, then a commercial failure is a therapeutic failure. A molecule that works and does not reach a patient has the same clinical outcome as a molecule that does not work. The difference lies only in where the failure gets recorded.

Key Takeaways

• Three unrelated kinds of firm answer to the same search words, and the category of help matters more than the choice of vendor.
• Strategy and analytics firms deliver recommendations at scale, and the engagement often ends before the operating model changes.
• Benchmarking firms tell a company where it ranks, which is not the same as knowing which journey breaks or who owns the break.
• Creative agencies shape what a customer sees, and almost everything determining whether a prescription becomes therapy happens where a campaign cannot reach.
• An external firm is the wrong purchase when nobody owns the problem, when a decision has already been taken, or when the real constraint is clinical or supply.
• Any engagement should be measured on the share of earned value that becomes sustained therapy rather than on how customers say they feel.

Diagnostic Questions to Consider

1. Name the single executive accountable for what happens between a prescribing decision and a patient on sustained therapy.
2. State whether the firms you are considering will measure sentiment or progression, and what each has proposed as evidence.
3. Describe what will remain inside the organization once the engagement ends, in terms of instrumentation, cadence and named owners.
4. Identify which of the three paths carries your largest loss today, and the number you can attach to it.
5. Decide whether the question you actually have is a benchmark question, a research question or a governance question.

Closing Reflection

Buying advice is mostly an exercise in matching a problem to a category, and the category here has no agreed label. That leaves commercial leaders doing vendor diligence on a question they have not yet framed. The framing is the work, and it is cheaper than the first engagement.

I have come to think the most useful service anyone in this market can offer is a clear account of what they are wrong for. A firm that cannot say that has either not met its own limits or has decided not to mention them. Either way, the buyer ends up discovering those limits on their own budget.

The science in this industry is frequently extraordinary and the experience surrounding it is frequently ordinary. Closing that gap requires no discovery, which is what makes it the most solvable problem in pharma and the most neglected. It asks only that someone be accountable for the whole distance between a decision and a patient who is actually better.

About the Author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.